TKUN Statistics

Total Valuation

Tikun Olam-Cannbit Pharmaceuticals has a market cap or net worth of ILS 26.62 million. The enterprise value is 32.07 million.

Market Cap	26.62M
Enterprise Value	32.07M

Important Dates

The next estimated earnings date is Thursday, November 28, 2024.

Earnings Date	Nov 28, 2024
Ex-Dividend Date	n/a

Share Statistics

Tikun Olam-Cannbit Pharmaceuticals has 80.92 million shares outstanding. The number of shares has increased by 1.37% in one year.

Shares Outstanding	80.92M
Shares Change (YoY)	+1.37%
Shares Change (QoQ)	-22.16%
Owned by Insiders (%)	50.13%
Owned by Institutions (%)	4.48%
Float	40.36M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.44
PB Ratio	1.20
P/FCF Ratio	6.32
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.64
EV / Sales	0.75
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	7.62

Financial Position

The company has a current ratio of 0.60, with a Debt / Equity ratio of 2.94.

Current Ratio	0.60
Quick Ratio	0.46
Debt / Equity	2.94
Debt / EBITDA	n/a
Debt / FCF	4.14
Interest Coverage	-24.57

Financial Efficiency

Return on equity (ROE) is -172.60% and return on invested capital (ROIC) is -62.36%.

Return on Equity (ROE)	-172.60%
Return on Assets (ROA)	-45.53%
Return on Capital (ROIC)	-62.36%
Revenue Per Employee	850,920
Profits Per Employee	-1.00M
Employee Count	51
Asset Turnover	0.61
Inventory Turnover	3.56

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -2.90% in the last 52 weeks. The beta is 0.83, so Tikun Olam-Cannbit Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.83
52-Week Price Change	-2.90%
50-Day Moving Average	32.79
200-Day Moving Average	33.96
Relative Strength Index (RSI)	66.44
Average Volume (20 Days)	44,038

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Tikun Olam-Cannbit Pharmaceuticals had revenue of ILS 42.55 million and -50.05 million in losses. Loss per share was -0.87.

Revenue	42.55M
Gross Profit	3.67M
Operating Income	-50.88M
Pretax Income	-51.04M
Net Income	-50.05M
EBITDA	-21.60M
EBIT	-50.88M
Loss Per Share	-0.87

Full Income Statement

Balance Sheet

The company has 4.18 million in cash and 17.45 million in debt, giving a net cash position of -13.27 million or -0.16 per share.

Cash & Cash Equivalents	4.18M
Total Debt	17.45M
Net Cash	-13.27M
Net Cash Per Share	-0.16
Equity (Book Value)	5.94M
Book Value Per Share	0.27
Working Capital	-10.33M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.29 million and capital expenditures -77,000, giving a free cash flow of 4.21 million.

Operating Cash Flow	4.29M
Capital Expenditures	-77,000
Free Cash Flow	4.21M
FCF Per Share	0.05

Full Cash Flow Statement

Margins

Gross margin is 8.63%, with operating and profit margins of -119.59% and -117.64%.

Gross Margin	8.63%
Operating Margin	-119.59%
Pretax Margin	-119.95%
Profit Margin	-117.64%
EBITDA Margin	-50.78%
EBIT Margin	-119.59%
FCF Margin	9.90%

Dividends & Yields

Tikun Olam-Cannbit Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.37%
Shareholder Yield	-1.37%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on January 22, 2017. It was a reverse split with a ratio of 0.002.

Last Split Date	Jan 22, 2017
Split Type	Reverse
Split Ratio	0.002

Scores

Tikun Olam-Cannbit Pharmaceuticals has an Altman Z-Score of -11.42. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-11.42
Piotroski F-Score	n/a